



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

FIRST NAMED INVENTOR:	SERIAL NO:	FILING DATE	ART UNIT:	PAPER NO.	
Hildegard M. Kramer	10/075,355	Feb. 14, 2002	1633		
TITLE: EXAMINER:					
Biocompatible Fleece For Hemostasis and Tissue Engineering Not Yet Assign					

Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

PECEIVED
DEC 1 8 2002
TECH CENTER 1600/2600 This Information Disclosure Statement herewith is being filed before the mailing of a first Office Action on the merits.

Applicants submit form PTO-1449 for consideration under CFR § 1.97(b) along with copies of the references listed #1-39.

Certain of the listed references were cited in the International Search Report dated November 11, 2002 issued in the corresponding PCT application (copy attached herewith).

Applicants believe that no fee is due with this submission.

However, if any additional fees are required, the Commissioner is authorized to charge the said fees to Deposit Account No. 07-1074.

Respectfully submitted,

Date: December 13, 2002

Isabelle A. S. Blundell, Ph.D. Attorney for Applicants

Registration No. 43,321

GENZYME CORPORATION

Legal Department One Kendall Square

Cambridge, Massachusetts 02139

Tel. (617) 591-5698 Fax. (617) 252-7977

Desktop Fax (617) 728-9558

Email: isabelle.blundell@genzyme.com

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QNB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) 1 of 3

Sheet

Complete if Known				
Application Number	10/075,355			
Filing Date	February 14, 2002			
First Named Inventor	Hildegard M. Kramer			
Group Art Unit	1633			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	5190			

			U.S. PATENT D	OCUMENTS		
iner	Cito	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
its *	Cite No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
	1	US- 4,511,478	04/16/85	Nowinski et al.		
	2	US- 4,741,872	05/03/88	De Luca et al.		
	3	US- 4,826,945	05/02/89	Cohn et al.		
	4	US- 4,846,835	07/11/89	Grande		
	5	US-4,888,413	12/19/89	Domb	P	
	6	US-4,938,763	07/03/90	Dunn et al.	PECK	.
	7	US-4,947,840	08/14/90	Yannas et al	Š	11/1
	8	US-5,041,138	08/20/91	Vacanti et al.		
	9	US- 5,100,992	03/31/92	Cohn et al.	7	
	10	US- 5,160,745	11/03/92	De Luca et al.	ECHA	2002
	11	US- 5,206,023	04/27/93	Hunziker	CENTE	
	12	US- 5,326,357	07/05/94	Kandel	TEH 16	۱.
	13	US- 5,410,016	04/25/95	Hubbell et al.	TECH CENTER 160	10/20na
	14	US- 5,466,462	11/14/95	Rosenthal et al.		17000
	15	US- 5,527,864	06/18/96	Suggs et al.		
	16	US-5,700,476	12/23/97	Rosenthal et al.		l
	17	US- 5,709,854	01/20/98	Griffith-Cima et al.		l
	18	US- 5,723,331	03/03/98	Tubo et al.		i
	19	US- 5,800,537	09/01/98	Bell		
	20	US- 5,837,278	11/17/98	Geistlich et al.		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁸ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
	21	WO 98/22154	05/28/98	Tissue Engineering, Inc.		
	22	WO 98/55594	12/10/98	Genzyme Corporation		
	23	WO 00/09179	02/24/00	Verigen Transplantation Service Inter.		
	24	WO 01/02033	01/11/01	Ethicon, Inc.		
	25	WO 01/06973	02/01/01	United States Surgical Corp.		
	26	WO 01/08610	02/08/01	Verigen Transplantation Service Inter.		

78	 	
Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Cffice. U.S. Pattern and Trademond Office. Washington, DC 2021. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

5190

Substitute for form Company 14, 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number

Filing Date

February 14, 2002

First Named Inventor

Hildegard M. Kramer

Group Art Unit

1833

Examiner Name

Not Yet Assigned

Sheet

of 3

			U.S. PATENT I	OCUMENTS	
Examiner Cite		Cite Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Initials •	No.1	Number - Kind Code ² (If known)	MM-DD-YYYY		Passages or Relevant Figures Appear
	27	US- 5,837,752	11/17/98	Shastri et al.	
	28	US- 5,900,245	05/04/99	Sawhney et al.	
	29	US- 6,027,744	02/22/00	Vacanti et at.	
	30	US- 6,083,524	07/04/00	Sawhney et al.	
	31	US- 6,206,931	03/27/01	Cook et al.	A)
	32	US- 2001/0051834A1	12/13/01	Frondoza et al.	70
	33	US- 2002/0025308A1	02/28/02	Costantino et al.	,
		US-			000
		US-			EC.
		US-			ECHCON
		US-			CNICA
		US-		1	1479
		US-			1
		US-			
	1	US-			1
		US-			

Attorney Docket Number

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵	
	34	EP 0 747 068	12/11/96	Johnson & Johnson Medical,Inc.			
	35	EP 1 064 958	01/03/01	Ethicon, Inc.	,		
	-						
				1			

Examiner	Date	1
Signature	Considered	i j

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is astimated to take 2.0 hours to complete. There will vary depending upon the needs of the inclinifications. Any comments on the amount of time you are required to complete this time modulable sent to the Chief Information Officer, U.S. Patient and Traderiark.

Office, Washington, D.C. 2023. I.D O NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, D.C. 2023.

¹ Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at https://www.uspto.og.go/mRFPP-901.04. 2 Feined Office that issued the document, by the two-letter code (VIPPO Standard ST 3.). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the potent document. * Kind of document by the appropriate symbols as indicated on the document under WIPPO Standard ST 1.6 if possible. * * Applicant is to place a check mark here II English language Transistion is statched.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. ONB 0561-0031.

U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Office Reduction Act of 1995, no persons are required to reapond to a colocitor of influenciator usines us

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Complete if Known Application Number 10/075 355 Filing Date February 14, 2002 First Named Inventor Hildegard M. Kramer Group Art Unit 1633 Examiner Name Not Yet Assigned

(use as many sheets as necessary)

Sheet

of 3 Attorney Docket Number 5190

		100
	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	Q.
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
36	BRITTBERG, Mats, M.D., et al. "Treatment of Deep Cartilage Defects in the Knee with AutoLogous Chondrocyte Transplantation", <i>The New England Journal of Medicine</i> , Vol. 331, No. 14, pp. 889-895 (1894)	
37	UCHIO, Y., et al., "Human Chondrocyte proliferation and matrix synthesis cultured in Atelocollagen® gel", J. Biomed Mater Res, Vol. 50, pp. 138-143, (2000)	
38	ELISSEEFF, J., et al., "Photoencapsulation of chondrocytes in poly(ethylene oxide)-based semi-interpenetrating networks", J. Biomed Mater Res., Vol. 51, pp. 164-171 (2000)	
39	"The Fibrin Network in Tissue Engineering", Baxter Hyland Immuno, pp. 1-38	
	36 37 38	Oite No. the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. number(s), publisher, city and/or country where published. BRITTBERG, Mats, MD., et al. Treatment of Deep Cartilage Defects in the Knee with AutoLogous Chondrocyte Transplantation, The New England Journal of Medicine, Vol. 331, No. 14, pp. 889-895 (1984) UCHIO, Y., et al., "Human Chondrocyte proliferation and matrix synthesis cultured in Atelocollagen® gel", J. Blomed Mater Res., Vol. 50, pp. 138-143, (2000) BUSSEEFF, J., et al., "Photoencapsulation of chondrocytes in poly(ethylene oxide)-based semi-interpenetrating networks", J. Blomed Mater Res., Vol. 51, pp. 164-171 (2000)

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Stalement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark. Office, Washington, DC 2021: DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 2023: 1.